The NHS in England has started offering liquid biopsies to some women with breast cancer that has mutated. These circulating tumour DNA (ctDNA) blood tests will show whether women with ER-positive HER2 negative secondary breast cancer have developed the ESR1 mutation which can sometimes occur after long-term treatment with hormone therapy. ER-positive cancer cells are…
Olaparib (Lynparza) has now been approved by NICE as a second-line treatment of HER2-negative locally advanced or metastatic breast cancer in adults with mutated BRCA1 or BRCA2 genes who have had chemotherapy. Olaparib is a PARP inhibitor; PAPR is a protein which helps cancer cells repair themselves and Olaparib stops this repair process in these…
In 2024 thanks to donors and fundraisers Secondary1st funded the first year of a research project led by Professor Simak Ali at Imperial College London investigating how changes in the ER gene contribute to hormone therapy resistance. About 44,000 people are diagnose with ER (oestrogen receptor) positive breast cancer each year in the UK and…
The wonderful Alina, a specialist breast cancer nurse, arranged a pre-Christmas afternoon of music and song by courtesy of the Wellington Hospital. Three brilliant stars of musical theatre sang favourite songs from popular shows with keyboard accompaniment and helped to raise more than £600 for Secondary1st.